Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + trastuzumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy involves the immune checkpoint inhibitor pembrolizumab, the HER2-targeted monoclonal antibody trastuzumab, and a chemotherapy backbone (such as FLOT or fluoropyrimidine-platinum doublets). It is being investigated by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of HER2-positive esophagogastric cancers, including esophageal cancer, gastric adenocarcinoma, and gastroesophageal junction (GEJ) adenocarcinoma. Trastuzumab blocks HER2 proteins that promote tumor growth, while pembrolizumab inhibits the PD-1/PD-L1 pathway to enhance T-cell anti-tumor activity. The chemotherapy component (including agents like oxaliplatin, 5-fluorouracil, and docetaxel) provides additional cytotoxic effects. These trials evaluate the combination in both metastatic and resectable (perioperative) settings to improve clinical outcomes in HER2-positive patients.
- Brand names
- KeytrudaHerceptin
- Other names
- MSKCC esophagogastric regimenpembrolizumab plus trastuzumab and chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pembrolizumab + trastuzumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + trastuzumab + chemotherapy.